AB Science announces plans to submit to Health Canada under NOC/c for masitinib

February 24, 2022 – Earlier this week, AB Science announced an intention to file a New Drug Submission (NDS) to Health Canada for its ALS drug masitinib under the Notice of Compliance with Conditions (NOC/c) pathway.

Once AB Science submits its application – and Health Canada accepts it – the next step would be a thorough review under the NOC/c pathway. The NOC/c pathway is a 200-day process, compared to a standard 300-day process, designed to potentially provide earlier access to therapies with specific conditions in place. You can read more about the NOC/c pathway here.

We will continue to post updates as we become aware of them. You can read more in AB Science’s press release. Specific questions about the treatment can be directed to the ALS Canada Research Team at research@als.ca.